Regulon

Quick links to important sections

Regulon

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Regulon

Quick Facts

Property Description
Active ingredient Desogestrel, Ethinyl Estradiol
Form Film-coated tablet
Pharmacological class Progestogens and Estrogens (Hormonal Contraceptive)
Common use Contraception / Prevention of pregnancy
Origin Synthetic hormone preparation

Defining Regulon: Classification and Type

Regulon is a brand name for a Combined Oral Contraceptive (COC), a prescription-only medication classified pharmacologically under Progestogens and Estrogens. This classification denotes a medicine that utilizes two distinct synthetic sex hormones for its therapeutic effect. The preparation is a synthetic hormone product, supplied as a film-coated tablet designed for oral administration. Regulon is recognized for its use in systemic hormonal modulation, which is applied for achieving contraception in women of childbearing age.


Composition: The Synthetic Hormone Components

The core functional components of Regulon are the synthetic active ingredients: the progestin Desogestrel and the estrogen Ethinyl Estradiol. Desogestrel is recognized as a third-generation synthetic progestogen, a chemical distinction related to its activity profile when compared to older progestins. The combination of these two components is engineered for a dual-action approach. This particular estrogen and progestin combination is designed to suppress the processes required for fertility.


Primary Purpose: The General Contraceptive Benefit

The singular, intended purpose of Regulon is to provide reliable contraception, effectively serving for the prevention of pregnancy. The combined components facilitate this through established physiological actions, including the suppression of egg release from the ovaries, known as ovulation inhibition. These actions, alongside alterations to the cervical mucus and the uterine lining, establish the medication as a systemic method for birth control. This medicine is typically chosen by patients seeking a monophasic regimen with a third-generation progestin.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Regulon?

Possible Side Effects and Safety Information

The safety profile of Regulon (Desogestrel/Ethinyl Estradiol) is documented by regulatory agencies and classified by frequency and affected physiological systems. The primary safety concern is the risk of serious vascular thromboembolic events (VTE), which include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (heart attack).

This serious risk is highest during the first year of use and upon restarting therapy after a break of four weeks or more. Safety labeling specifies that the risk of these cardiovascular events is markedly increased in women over 35 years of age who smoke.

Frequency-Classified Adverse Reactions

Adverse reactions that are formally classified by frequency in regulatory documents include:

  • Common: Nausea, headache, dizziness, abdominal pain, increased weight, depressed or altered mood, and breast pain/tenderness. Breakthrough bleeding or spotting is a common occurrence, particularly during the initial three months of use.
  • Uncommon: Vomiting, diarrhea, migraine, fluid retention, rash, and changes in libido.
  • Rare: Serious reactions like VTE, as well as hypersensitivity reactions and decreased body weight.

Systemic Safety Considerations

Side effects are categorized by System-Organ Classes, including Nervous System Disorders, Gastrointestinal Disorders, and Reproductive System and Breast Disorders. Rarely, the official label includes the documented risk of hepatic neoplasia (benign liver tumors) and, even less frequently, hepatocellular carcinoma, which has been associated with long-term exposure.

Regulatory Constraints: The medicine does not protect against HIV infection (AIDS) or other sexually transmitted diseases. Furthermore, official guidance requires discontinuation at least four weeks prior to and for two weeks after elective surgery associated with an increased risk of thromboembolism.

Overdose and Emergency Response

Regulon Overdose and when to seek help

Official regulatory documentation classifies the acute effects of Regulon overdose as generally not likely to be life-threatening. Authorities state that no serious harmful effects have been widely reported following acute ingestion of a large dose.

Domain Official Regulatory Statement
Documented Overdose Manifestations Nausea, vomiting, and withdrawal bleeding (vaginal bleeding/spotting) are the most commonly reported symptoms.
Immediate Action Required Individuals are instructed to seek medical help right away and to contact a Poison Control Center immediately.
Management & Antidote Management is confined to symptomatic and supportive treatment. Authorities confirm that no specific antidote is known.
Population Note Slight vaginal bleeding may occur in young girls (prepubertal females) who have ingested a large dose.

The regulatory profile establishes that while acute overexposure is not anticipated to cause severe toxicity, its hormonal effects necessitate immediate medical consultation. The required emergency action is to seek prompt professional help, as the established course of treatment is purely supportive, focused on managing the documented transient manifestations.

Therapeutic Uses of Regulon

Quick Facts: What Regulon treats

  • Prevents pregnancy for contraception.

Regulon is indicated for the prevention of pregnancy in individuals of childbearing potential. As a form of hormonal contraception, its primary use is to mitigate the risk of conception when administered as prescribed. This benefit allows for planned control of reproductive timing.

An important secondary application involves the management of certain menstrual cycle disorders by facilitating a predictable bleeding schedule. It is frequently employed to alleviate symptoms of moderate to severe primary dysmenorrhea (painful periods) and to promote regularity of menstrual cycles. Patients using this medication report the benefit of establishing a regular bleeding pattern.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Regulon — Official Regulatory Information

The use of Regulon (Desogestrel, Ethinyl Estradiol) is strictly defined by government regulatory standards, which establish specific populations for whom the medicine is either permitted, restricted, or absolutely prohibited.


Category Regulatory Eligibility Statement
Populations for whom use is allowed Females of childbearing potential seeking contraception.
Populations for whom use is contraindicated Women with a history of blood clots (VTE, PE, stroke, or heart attack) or predisposing conditions; hormone-sensitive cancers (e.g., breast cancer); severe liver disease or tumors; or undiagnosed abnormal genital bleeding.
Age-related eligibility rules Use is contraindicated in women over age 35 who smoke. Use is not indicated in the elderly, and should not be initiated before menarche.
Condition-specific eligibility rules Prohibited for those with diabetes mellitus with vascular damage, or uncontrolled hypertension.
Pregnancy and lactation status Contraindicated during pregnancy. Not recommended during breastfeeding in the immediate postpartum period.

Eligibility Classifications (High-Level)

  • Eligibility severity classification: Contraindicated, Not Recommended, Use Not Established.
  • Eligibility-context constraints: Cardiovascular and Thromboembolic risk, Hormone-sensitive cancer risk, Hepatic function status.

Connection to the overall eligibility profile Regulatory documents define eligibility primarily through absolute contraindications, which prohibit use based on pre-existing risks that the combined hormones may exacerbate, such as thromboembolic history and specific malignancies. This structure restricts approved use to women of reproductive age who are free from these specific prohibitive medical conditions. The profile functions as a non-negotiable set of exclusion criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Regulon (Desogestrel / Ethinyl Estradiol) is defined by pharmacokinetic interactions that primarily alter the systemic exposure of the hormonal components, alongside specific combinations designated as contraindicated.

Contraindicated Combinations

Certain combinations are formally prohibited due to the risk of serious adverse outcomes. Co-administration is contraindicated with certain Hepatitis C Virus (HCV) medicinal products (including regimens with Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir) due to the documented risk of significant liver enzyme (ALT) elevations. Additionally, co-administration with oral Tranexamic Acid is contraindicated due to a documented increase in the risk of thromboembolic events.

Pharmacokinetic Interactions (Exposure Changes)

The systemic exposure of Regulon's hormones may be altered by co-administered medicines that affect metabolic clearance, mainly through the CYP3A4 enzyme system.

Interaction Type Examples (Specific Medicines / Class) Effect on Regulon Exposure
Enzyme Induction Carbamazepine, Rifampicin, St John’s Wort Clearance increased; Exposure decreased
Enzyme Inhibition Fluconazole, Itraconazole Clearance reduced; Exposure increased

Timing and Secondary Drug Effects

Following the discontinuation of a strong hepatic enzyme inducer, regulatory documents require the use of a barrier method of contraception for 28 days. Regulon itself may also affect the clearance of other medicines; for instance, it is documented to reduce the exposure of Lamotrigine while increasing the exposure of Tizanidine and Cyclosporine.

Mechanism of Action

The mechanism results from the combined action of its two synthetic hormone components, etonogestrel and ethinylestradiol, which results in layered physiological modulations by acting as agonists at Progesterone (PR) and Estrogen (ER) receptors.

Central Suppression of the Hormonal Control Axis

This domain involves the primary mechanism: the continuous activation of PR and ER in the hypothalamus and pituitary glands. This action imposes strong negative feedback that dramatically reduces the release of FSH and LH. The resultant physiological consequence is the complete failure of the mid-cycle LH surge, leading directly to anovulation (the non-release of an egg).

Peripheral Barrier and Tissue Modification

This domain covers the secondary actions on the reproductive tract. The hormonal components target peripheral receptors to alter the biophysical properties of cervical mucus, significantly increasing its viscosity, resulting in a physical barrier function. Concurrently, they modulate the endometrium (uterine lining), inhibiting its proliferation and creating an altered tissue structure. This combined effect results in secondary physiological modulation reinforcing the central mechanism.

Dosage and Administration Information

How to Use Regulon

Regulon is administered through the oral route as a film-coated tablet, following a continuous, cyclical regimen. The standard approach involves a 28-day cycle using a fixed-dose monophasic formulation containing 0.15 mg Desogestrel and 0.03 mg Ethinyl Estradiol.


Dosing and Schedule Principles

Administration is structured around the frequency of once daily (qDay) dosing. A principle of this regimen is maintaining Fixed Daily Dose Timing: the tablet is ingested at the same time each day to maintain hormone levels. The 28-day cycle involves taking one active tablet for 21 consecutive days, followed immediately by one inactive (placebo) tablet for the subsequent 7 days. Following the 28-day regimen, a new cycle is started without interruption, regardless of the timing or status of withdrawal bleeding.

Contextual Usage Instructions

The initiation of treatment follows Treatment Initiation Protocols, typically starting on either the first day of the menstrual period (Day 1 Start) or the first Sunday following the period onset (Sunday Start). The tablets may be taken with or without food. For the regimen to follow standard patterns, patients initiating with the Sunday Start or when switching from a non-hormonal method utilize a non-hormonal barrier method for the first 7 days of the first cycle. The adult dosing schedule is applicable for postpubertal adolescents. The usage pattern includes specific Missed-Dose Rules for active tablets, which outline procedural steps for instances when a dose is missed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Regulon

This section outlines the structure of the clinical research for Regulon (Desogestrel / Ethinyl Estradiol), describing what outcomes research has explored and what patterns were observed, without making any claims about effectiveness or providing medical advice. The information is based on authoritative governmental and peer-reviewed scientific sources.


Evidence Base for Pregnancy Prevention (Contraception)

The research examined the medicine in the context of prevention of pregnancy (contraception). The evidence base includes both controlled clinical trials (RCTs) and long-term observational studies exploring outcomes.

Researchers examined contraceptive efficacy by monitoring the Pearl Index, which is the standardized measure for pregnancy rates, and also applied measurements of ovulation suppression, which is a functional physiological outcome studied in the trials. Large-scale observational data reported measurements of unintended pregnancy rates observed during typical use. Findings describe patterns where ovulation suppression was measured in the study participants.


Research on Management of Menstrual Symptoms

Research examined the medicine's use for conditions characterized by fluctuating or episodic manifestations (primary dysmenorrhea) and for establishing menstrual cycle regularity. This research primarily utilized Randomized Controlled Trials (RCTs) summarized within systematic reviews.

Studies evaluated patient-reported outcomes describing perceived discomfort, such as pain intensity, which was measured during the study period using standardized scales. Research also monitored the use of rescue pain medication and tracked the incidence of unscheduled bleeding. Findings describe patterns observed in the studies where measured changes in reported pain intensity occurred in cohorts of women experiencing primary dysmenorrhea.


Areas of Research Uncertainty and Limitations

The research landscape contains several known limitations. The effectiveness rates reported in controlled trials may not perfectly predict individual outcomes because the performance was observed in some studies to be sensitive to variations in user adherence. Furthermore, evidence quality varies across studies within the COC class. Sample sizes were modest in some comparison trials, and comparative evidence is lacking for direct comparison against every other combined hormonal contraceptive. Findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Regulon (FAQ)


Q: Is Regulon only for the main condition or other things too?

According to official documents, the primary intended purpose of Regulon is the prevention of pregnancy (contraception). Studies and regulatory summaries also indicate that the medication may be used to manage certain menstrual symptoms, such as reducing the discomfort associated with primary dysmenorrhea (painful periods).


Q: What are the most common types of substances that interact with Regulon?

Official information describes that interactions are mostly linked to medicines that affect hepatic enzymes (the body's natural clearing system), which can change the level of hormones in the blood. Certain prescription medications, like specific anticonvulsants or antifungals, are examples of drugs that interact this way. Additionally, the label specifically contraindicates the use of certain Hepatitis C treatments and the antifibrinolytic drug Tranexamic Acid.


Q: Are the reported side effects of Regulon generally considered serious?

The main safety concern noted in regulatory warnings is the rare risk of serious vascular thromboembolic events (VTE), which include conditions like blood clots, stroke, or heart attack. However, the most common side effects reported, such as headache, nausea, and changes in mood, are generally less serious and may diminish as the body adjusts.


Q: Is Regulon a medication that is designed to be taken long-term?

Official prescribing information indicates that Regulon is designed for a continuous, cyclical regimen taken every day. The medication is intended for use over an extended period to maintain reliable contraceptive protection.


Q: Is it normal to feel no immediate change when first starting treatment with Regulon?

The primary mechanism of Regulon—the inhibition of ovulation—is a functional change that is typically not felt immediately. If changes are experienced, the most common are usually mild and include temporary symptoms like breakthrough bleeding or spotting during the first few cycles.


Q: Why might patient communities discuss Regulon helping with conditions other than its primary use?

Combination hormonal contraceptives are associated with health effects beyond their main purpose of preventing pregnancy. These are often referred to as non-contraceptive benefits. These include establishing greater menstrual cycle regularity and decreasing menstrual pain, which are frequently discussed outcomes in patient settings.


Q: What is the general expectation for duration of treatment with Regulon?

The expectation is that treatment with Regulon is continued for as long as contraception is desired and the patient remains eligible to use the medication. Use of the medication is based on adherence to the daily, cyclical regimen and compliance with the official contraindications.


Q: Does Regulon interact with caffeine or energy drinks?

Official drug information indicates that the estrogen component of Regulon (Ethinyl Estradiol) may increase the amount of caffeine that stays in the body. While usually a minor interaction, this could potentially worsen caffeine-related symptoms such as nervousness or nausea.


Q: How quickly should I expect Regulon to start producing its intended effect?

The body requires at least 7 days of continuous dosing to adjust to the hormones and establish contraceptive protection. Official patient instructions indicate that a second form of contraception, such as a barrier method, is utilized for the first 7 days of the first cycle.


Q: How long after starting Regulon should a patient notice a potential difference?

The most commonly noticed change is breakthrough bleeding or spotting, which is frequently reported, especially during the first three months of use. Other mild side effects like nausea may also occur during the initial adjustment period.


Q: What is the recommended information for when someone experiences a rare side effect mentioned in the official leaflet?

Official regulatory guidance states that emergency medical help is sought immediately if symptoms indicative of a serious, rare side effect—such as signs of a blood clot, stroke, or heart attack—are experienced.


Q: Can Regulon be taken with common pain relievers like ibuprofen or acetaminophen?

Regulatory data notes that Acetaminophen (Paracetamol) is known to interact with the estrogen component of Regulon, although this interaction is typically minor. The concurrent use of common pain relievers is usually managed through consultation with a healthcare professional due to the potential for interaction variability.


Q: Is there a generic version of Regulon currently available on the market?

Yes, the active ingredients in Regulon, Desogestrel and Ethinyl Estradiol, are available under a variety of generic brand names. These generic options come in different formulations, including monophasic, biphasic, and triphasic regimens.


Q: What are the official sources of information about Regulon?

Reliable, official sources of information include the Prescribing Information (SmPC or DailyMed) and Patient Information Leaflets published by government regulatory agencies. These documents provide the factual, verified details regarding the drug's use and safety profile.


Q: Can Regulon be taken if a person has certain allergies?

Official eligibility criteria state that the medication is contraindicated (should not be used) if a person has a known hypersensitivity to Desogestrel, Ethinyl Estradiol, or any of the other inactive components of the tablet.


Q: Does Regulon require any regular testing or monitoring during treatment?

Official guidance recommends that regular follow-up visits with a healthcare provider occur during treatment. This monitoring often includes checks for blood pressure, breast examinations, and cervical cytology. Specific risk factors may also lead to monitoring of lipid levels or liver function.


How should Regulon be stored and disposed of?

Storage Requirements

Regulon tablets must be stored at a temperature below 25, C to maintain their stability. Regulatory instructions strictly prohibit refrigeration or freezing of the medicinal product. The tablets must be kept in the original package and the outer carton to ensure they are protected from light and moisture. The medicine should not be used after the expiry date printed on the packaging.

Child Safety and Disposal

For safety, Regulon must be kept out of the sight and reach of children.

Disposal instructions require that unused or expired tablets not be thrown away via wastewater or household waste. Disposal must be managed in accordance with local regulations for pharmaceutical products. Consult a pharmacist for guidance on proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Regulon found in:

A-Z Index: